Case Report

High-grade spheno-orbital meningioma in patients with systemic lupus erythematosus: Two case reports and literature review

Sarah Bin Abdulqader¹, Nasser Almujaiewl², Wafa Alshakweer³, Gmaan Alzhrani¹

¹Department of Neurosurgery, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia; ²College of Medicine, King Saud University, Riyadh, Saudi Arabia; ³Department of Pathology and Clinical Laboratory Medicine, King Fahad Medical City, Riyadh, Saudi Arabia.

E-mail: Sarah Bin Abdulqader - binabdulqader@gmail.com; Nasser Almujaiewl - nasser.almujaiewl@gmail.com; Wafa Alshakweer - walshakweer@kfmc.med.sa; *Gmaan Alzhrani - gmaan1111@gmail.com

ABSTRACT

Background: Spheno-orbital meningiomas (SOMs) are often benign. The association of meningioma and systemic lupus erythematosus (SLE) is rarely discussed in the literature. Here, we report two patients with high-grade SOMs with a prolonged history of SLE and review the literature.

Case Description: The first case is a 52-year-old female patient with a 15-year history of SLE diagnosis who was referred to our center with a 1-year history of proptosis and excessive tearing of the left eye. This patient was operated for the left SOM with histopathological diagnosis of the World Health Organization (WHO) Grade III rhabdoid meningioma. The second case is a 36-year-old female patient with a 12-year history of SLE diagnosis who presented to our clinic with a 5-year-history of progressive right eye proptosis and occasional headaches. She was operated for the right SOM with histopathological diagnosis of the WHO Grade II chordoid meningioma.

Conclusion: Rhabdoid and chordoid SOMs are uncommon and no previous report discussed their occurrence in patients with SLE. The association of high-grade meningiomas and SLE deserves further exploration.

Keywords: Chordoid meningioma, Rhabdoid meningioma, Spheno-orbital meningioma, Systemic lupus erythematosus

INTRODUCTION

Spheno-orbital meningioma (SOM) is a complex and unique pathological condition that accounts for 9% of all intracranial meningiomas.¹²,39 These tumors originate from the dural sheath of the sphenoid bone and are characterized by their invasion into the orbit, optic canal, superior orbital fissure, and cavernous sinus. Intersosseous tumor growth in SOM results in hyperostosis and soft-tissue growth.¹¹,¹²,25,43,52 Patients with SOM classically present with proptosis, vision loss, limited ocular motility, and headache.¹²,23,39,91 SOMs are often low grade. High-grade meningiomas, such as Grade II and Grade III, in the spheno-orbital region are rare.¹²,56 Furthermore, among the different types of high-grade meningiomas, chordoid and rhabdoid SOMs in particular are rarely encountered.

Systemic lupus erythematosus (SLE) is an autoimmune, multiorgan, connective tissue disease with diverse pathogenesis and unexplored etiology that frequently affects women.⁶⁰ Increased
risk of malignancies was observed in patients with SLE; however, no study has previously identified an increased risk of central nervous system (CNS) malignancies or high-grade meningiomas in patients with SLE.

In this paper, we describe two patients who were diagnosed with SLE and referred to us for the surgical treatment of SOM. These patients exhibited uncommon histopathological variants of SOM.

CASE REPORT

Case 1

A 52-year-old female patient with a 15-year history of SLE diagnosis was referred to our center with a 1-year history of proptosis and excessive tearing of the left eye. On examination, she was found to have a visual acuity of 20/20 in the right eye and 20/25 in the left eye, with intact extraocular movement and facial sensation. She had been on a regimen of azathioprine therapy to manage her SLE.

Radiological imaging showed left SOM with extension into the superior orbital fissure, left cavernous sinus, and left petrous apex. In addition, there was a small extension toward the left cerebellopontine angle (CPA) with significant hyperostosis of the sphenoid bone and lateral orbital wall [Figure 1]. Azathioprine therapy was discontinued preoperatively.

The patient was subsequently operated through the left pterional approach. The histopathological examination established a diagnosis of the World Health Organization (WHO) Grade III rhabdoid meningioma (RM) [Figure 2]. Postoperatively, the patient's recovery was uneventful. However, postoperative radiological imaging findings showed residual lesions at the left cavernous sinus and CPA that were not amenable to resection. The patient received external beam radiation therapy (EBRT; 60 Gy in 30 fractions) and showed gradual improvement of proptosis with no new neurological deficits.

Case 2

A 36-year-old female patient with a 12-year history of SLE diagnosis presented to our clinic with a 5-year history of progressive right eye proptosis and occasional headaches. On examination, she was found to have right eye exophthalmos with normal visual acuity, as well as intact extraocular motility and normal facial sensation bilaterally. She was on a regimen of hydroxychloroquine to manage her lupus. In addition, she used steroids, which was discontinued a year ago because of remission.

Radiological imaging findings showed right SOM with extension into the orbit and cavernous sinus [Figure 3].

Figure 1: Case 1. (a and b) Preoperative T1-weighted postgadolinium administration MR images demonstrating left SOM with extension into the superior orbital fissure, left cavernous sinus, left petrous apex, and left cerebellopontine angle (CPA). (c) Preoperative CT head bone window demonstrating hyperostosis. (d) Postoperative T1-weighted postgadolinium administration MR images demonstrating postoperative changes as well as residual lesion at the left cavernous sinus and CPA.

Figure 2: Case 1. Hematoxylin and eosin staining showing rhabdoid meningioma, ×20.

Right frontotemporal craniotomy was performed for tumor resection. The histopathological examination established a
Bin Abdulqader, et al.: High-grade spheno-orbital meningioma in patients with systemic lupus erythematosus

Diagnosis of the WHO Grade II chordoid meningioma (CM) [Figure 4]. Subsequent, postoperative follow-up imaging findings showed intraorbital residual lesion approaching the superior orbital fissure that was difficult to resect. The patient underwent EBRT (60 Gy in 30 fractions and 54 Gy in 30 fractions) using simultaneous integrated boost due to intraorbital component. The patient reported improvement of symptoms with no new neurological deficits.

Literature review methods

To investigate for previous reports of cases of meningioma occurring in patients with SLE, we searched the PubMed database using the following terms; meningioma AND “systemic lupus erythematosus,” meningioma AND “autoimmune disease,” and meningioma AND “connective tissue disease.” Data on age, sex, time of meningioma diagnosis, location of meningioma, histopathological grade of meningioma, and medications used for the treatment of SLE were collected for each case.

Literature review results

Seven cases were identified and were available for review in addition to one case that was retrieved through cited references. Ten cases were analyzed [including our two cases; Table 1]; all were female with a mean age at presentation of 47 years. The clinical presentation consists of headaches in 75% and psychiatric symptoms in 37%. The mean time from SLE diagnosis to the development of meningioma was 18 years. Four of the cases identified were operated; the histopathological data were available for two patients which determined benign (WHO Grade I) meningiomas. With regard to the medications used for the treatment of SLE, seven patients were receiving steroids, three were receiving azathioprine, five were receiving antimalarial medications, one was receiving mycophenolate mofetil, and one was receiving cyclosporine.

DISCUSSION

This report describes two rare histopathological variants of SOM that occurred in patients with a prolonged history of SLE. The association of meningioma and SLE has been discussed earlier,[10,13,42,49,59] however, no previous report discussed an association of high-grade meningioma and SLE.

Meningioma is the most common primary intracranial tumor in adults, accounting for one-third of all primary intracranial tumors, with a female-to-male ratio of 2:1; and most patients have low-grade meningioma.[36] High-grade, atypical (Grade II), and anaplastic (Grade III) meningiomas are rarely encountered in clinical settings, and they represent <10% of all meningiomas.[2,146]

RM is an uncommon variant of meningioma, which represents 0.28% of all meningioma;[60] it was first described two decades ago by Kepes et al.[28] and Perry et al.[37] Subsequently, in the 2000 WHO classification of CNS tumors, RM was added.
Table 1: Reported cases of meningioma in patients with systemic lupus erythematosus.

| Author          | Age/sex | Time from SLE diagnosis to meningioma diagnosis | Clinical presentation                                      | Meningioma location | Histopathology | SLE treatment                                                                 |
|----------------|---------|-----------------------------------------------|-----------------------------------------------------------|---------------------|----------------|-------------------------------------------------------------------------------|
| Bilaniuk et al., 1977[10] | 48/F    | Not reported                                  | Seizures and psychosis                                     | Tentorial           | Not reported                 | Steroids and hydroxychloroquine                                               |
| Richardson et al., 2000[42] | 68/F    | 44 years                                      | Headaches                                                  | Occipital           | Not operated               | Cyclophosphamide, steroids and azathioprine                                   |
| Castellino et al., 2009[13]  | 60/F    | 17 years                                      | Exophthalmos                                               | Retro-orbital       | Not operated               | Steroids and hydroxychloroquine                                               |
|                          | 39/F    | 14 years                                      | Headache, anxiety, severe depression, and panic attack     | Parietal            | Meningothelial, WHO Grade I       | Steroids and hydroxychloroquine                                               |
|                          | 54/F    | 7 years                                       | Headache, depression, and cognitive dysfunctions           | Falcine             | Not operated               | Steroids and cyclosporine                                                    |
| Sankaran et al, 2015[49]   | 30/F    | 1 year                                        | Headaches                                                  | Falcine             | Not reported               | Steroids, hydroxychloroquine, and mycophenolate mofetil                      |
|                          | 41/F    | 2 years                                       | Headaches and vomiting                                     | Convexity, frontal  | Not reported               | Steroids, hydroxychloroquine, and azathioprine                               |
| 49/F                      | 1 week  | Headaches                                     | Convexity, parietal                                         | Meningothelial, WHO Grade I       | Steroids and hydroxychloroquine                                               |
| 52/F                      | 15 years| Proptosis                                     | Sphenoidal, WHO Grade I                                    | Rhabdoid, WHO Grade III       | Steroids and hydroxychloroquine                                               |
| The present report        | 36/F    | 12 years                                      | Proptosis, decrease vision, and headaches                  | Sphenoidal, WHO Grade II       | Steroids and hydroxychloroquine                                               |

F: Female, WHO: World Health Organization

as a distinct Grade III malignant meningioma due to its aggressive course and malignant histological features. RMs are associated with poor prognosis, a relatively high risk of recurrence (87%), extracranial metastasis (13%), and death (53%). In addition, these tumors have bone involvement, with 56% of the tumors manifesting definite hyperostosis. CM was additionally introduced by Kepes et al. in their 1988 report. In their original report, they described seven cases of CM that occurred exclusively in children with Castleman’s syndrome. Subsequently, in 1993, CM was added to the WHO classifications of CNS tumors as a Grade II atypical meningioma. These tumors have histological features resembling those of chordoma and account for 0.5–1% of all intracranial meningiomas. Unlike RMs, CMs are less aggressive with a recurrence rate of 11–22%. Meningiomas of the cranial base show an indolent growth pattern and are often classified as low-grade meningiomas as compared with its noncranial base counterparts. The low-grade nature of these meningiomas has been theoretically attributed to the fact that most cranial base meningiomas present earlier; thus, cases of aggressive or malignant transformation are less likely to occur due to early intervention. In addition, cases of SOM represent a considerable surgical challenge because of its invasion into the cavernous sinus and superior orbital fissure; therefore, some authors argued that the primary goal of surgical treatment is to improve symptoms rather than complete resection.

High-grade SOMs, specifically RMs and CMs, are rare. Various case series have discussed the natural history and outcomes of SOMs and demonstrated that Grade I meningiomas occur in 78%, 83%, 84%, 87%, 90%, 94%, and 100% of the patients examined in these reports. In addition, in the previously discussed cases series, Grade II SOM constituted 5.6%, 9%, 10%, and 16% of the cases. Interestingly, Grade III meningiomas are the least reported among the three SOM grades, representing 3% and 10.5% of all SOMs. These case series, however, did not report on the specific subtypes of Grade II and Grade III SOMs. Sporadic cases of rhabdoid and chordoid sphenoidal meningiomas have been reported.

An association between SOM and other medical conditions, specifically, hypothyroidism has been identified; however, this association was not studied further. SLE is an inflammatory autoimmune disease with multiple organs involvement. The production of autoantibodies and...
serum cytokine dysregulation is pathognomonic of this disease. The risk of malignancies among patients with SLE has received more attention recently. A higher risk of hematological malignancies, lung cancer, bladder cancer, and gynecological malignancies has been observed among patients with SLE. Prevailing theories have proposed an association between malignancies and SLE, including relatively high expression of interleukin 6 (IL-6) and IL-10 in patients with non-Hodgkin lymphoma and in patients with SLE. Moreover, cyclophosphamide exposure has been reported as a risk factor for bladder cancer as was a higher susceptibility to specific viral infections such as Epstein–Barr virus and human papilloma virus in patients with SLE, both of which play a role in the pathogenesis of hepatobiliary and gynecological malignancies. IL-6 expression was suggested to be an important factor in the pathogenesis of CM; therefore, patients with SLE may have an increased risk of developing CM. Moreover, SLE is treated with a variety of medical therapies, including glucocorticoids, antimalarials (hydroxychloroquine, chloroquine, and mepacrine), methotrexate, azathioprine, cyclophosphamide, mycophenolate mofetil, calcium inhibitors (cyclosporine A and tacrolimus), thalidomide, rituximab, and belimumab. Only few studies have identified an increased risk of malignancies with the use of specific medications; they include an increased risk of hematological malignancies and lung cancer among patients on azathioprine therapy for rheumatoid arthritis but not for SLE, increased risk of bladder, skin, and hematological malignancies among patients on cyclophosphamide therapy for rheumatoid arthritis as well as increased risk of bladder cancer among patients on cyclophosphamide therapy for SLE. Nonetheless, the use of antimalarial drugs (e.g., hydroxychloroquine) was not associated with an increased risk of malignancies in patients with SLE. One of our patients was receiving azathioprine and the other one was receiving hydroxychloroquine.

The role of estrogen and progesterone receptors in the development of meningioma is well established. This was evident by accelerated growth of meningiomas during pregnancy and in postmenopausal women receiving exogenous hormone therapy. Moreover, Grade I meningiomas primarily affect females whereas males are more likely to be affected by high-grade meningiomas. SLE largely affects women with a female-to-male ratio of 9:1. This female predominance remains undetermined; however, the role of estrogen in the development of SLE was proposed.

From the current literature, we identified eight cases of meningiomas that were reported in patients with SLE. Histopathological date was available for two patients which determined benign (WHO Grade I) meningiomas. These reports suggested a possible role of estrogen and progesterone exposure in the pathogenesis of meningioma in those patients. Nonetheless, two previous studies failed to identify an increased risk of meningioma in patients with autoimmune diseases. These studies, however, did not stratify meningiomas based on their histopathological grading.

**CONCLUSION**

This report provides an insight into the possible attribution of SLE to the development of high-grade meningiomas. We report an unusual association between rare histopathological entities of SOM and SLE. The use of specific medications to manage SLE as well as the overexpression of IL-6 observed in both CM and SLE might play a role in the pathogenesis of high-grade (rhabdoid and chordoid) SOM. However, further epidemiological and genetic studies are needed to validate this association. Moreover, a coincidental association cannot be ruled out given that both meningioma and SLE are common disease conditions.

**Declaration of patient consent**

Patient’s consent not required as patients identity is not disclosed or compromised.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Arima T, Natsume A, Hatano H, Nakahara N, Fujita M, Ishii D, et al. Intraventricular chordoid meningioma presenting with Castleman disease due to overproduction of interleukin-6. Case report. J Neurosurg 2005;102:733-7.
2. Backer-Grondahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol 2012;5:231-42.
3. Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim CS, et al. Systemic lupus erythematosus is a risk factor for cancer: A nationwide population-based study in Korea. Lupus 2019;28:317-23.
4. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, MedsgerTA. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 1987;83:1-9.
5. Belinsky I, Murchison AP, Evans JJ, Andrews DW, Farrell CJ, Casey JP, et al. Spheno-orbital meningiomas: An analysis based on World health organization classification and Ki-
67 proliferative index. Ophthalmic Plast Reconstr Surg 2018;34:143-50.
6. Benson VS, Kirichek O, Beral V, Green J. Menopausal hormone therapy and central nervous system tumor risk: Large UK prospective study and meta-analysis. Int J Cancer 2015;136:2369-77.
7. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin PJ, Petri M, et al. Cancer risk in systemic lupus: An updated international multi-centre cohort study. J Autoimmun 2013;42:130-5.
8. Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, et al. Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus. J Rheumatol 2018;45:393-6.
9. Bikmaz K, Mrak R, Al-Mefty O. Management of bone-invasive, hyperostotic sphenoid wing meningiomas. J Neurosurg 2007;107:905-12.
10. Bilaniu LT, Patel S, Zimmerman RA. Computed tomography of systemic lupus erythematosus. Radiology 1977;124:119-21.
11. Boari N, Gagliardi F, Spina A, Balo M, Franzin A, Mortini P. Management of sphenoo-orbital en plaque meningiomas: Clinical outcome in a consecutive series of 40 patients. Br J Neurosurg 2013;27:84-90.
12. Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG, Black PM, et al. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer 2002;99:252-9.
13. Castellino G, Rizzo N, Bernardi S, Trotta F, Govoni M. Meningioma and systemic lupus erythematosus: A matter of pure coincidence? Lupus 2009;18:650-4.
14. Chen ZX, Peng XT, Tan I, Zhai GQ, Chen G, Gan TQ, et al. EBV as a potential risk factor for hepatobiliary system cancer: A meta-analysis with 918 cases. Pathol Res Pract 2019;215:278-85.
15. Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, Scheithauer BW, et al. Exogenous hormone use, reproductive factors, and EBV as a potential risk factor for hepatobiliary system cancer: A meta-analysis with 918 cases. Pathol Res Pract 2019;215:278-85.
16. Combs SE, Schulz-Ertner D, Debus J, von Deimling A, von Deimling A, Eppenberger EC, et al. Rhabdoid transformation of tumor cells in meningiomas: A histologic indication of increased proliferative activity: Report of four cases. Am J Surg Pathol 1998;22:231-8.
17. Donato G, Ferraro G, Signorelli F, Iofrida G, Lavano A, Al-Mefty O. Management of bone-invasive, hyperostotic sphenoid wing meningiomas: Optimizing visual outcome. J Neurosc Rural Pract 2020;11:367-77.
18. Couce M, Aker F, Scheithauer B. Chordoid meningioma: A clinicopathologic study of 42 cases. Am J Surg Pathol 2000;24:899-905.
19. Donato G, Ferraro G, Signorelli F, Iofrida G, Lavano A, Al-Mefty O, et al. Chordoid meningioma: Case report and literature review. Ultrastr Pathol 2006;30:309-14.
20. Drehmer M, Andrade D, Pereira I, Marrero A, Muniz Y, de Souza I, et al. Estrogen receptor alpha gene (ESR1) polymorphism can contribute to clinical findings in systemic lupus erythematosus patients. Lupus 2017;26:294-9.
21. Felten R, Scher F, Sibilia J, Chasset F, Arnaud L. Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. Joint Bone Spine 2019;86:429-36.
22. Forster MT, Daneshvar K, Senft C, Seifert V, Marquardt G. Spheno-orbital meningioma: Surgical management and outcome. Neuror Res 2014;36:695-700.
23. Freeman JL, Davern MS, Oushy S, Sillau S, Ormond DR, Youssef AS, et al. Spheno-orbital meningiomas: A 16-year surgical experience. World Neurosurg 2017;99:369-80.
24. Heufelder MJ, Sterker I, Trantakis C, Schneider JP, Meixensberger J, Hemprich A, et al. Reconstructive and ophthalmologic outcomes following resection of sphenoo-orbital meningiomas. Ophthalmic Plast Reconstr Surg 2009;25:223-6.
25. Honig S, Trantakis C, Frierich B, Sterker I, Kortmann RD, Meixensberger J. Meningiomas involving the sphenoid wing outcome after microsurgical treatment-a clinical review of 73 cases. Cent Eur Neurosurg 2010;71:189-98.
26. Honig S, Trantakis C, Frierich B, Sterker I, Schober R, Meixensberger J. Spheno-orbital meningiomas: Outcome after microsurgical treatment: A clinical review of 30 cases. Neurosurg 2010;2:164-215.
27. Kepes JJ, Chen WY, Connors MH, Vogel FS. Chordoid meningeal tumors in young individuals with peritumoral lymphoplasmacellular infiltrates causing systemic manifestations of the Castleman syndrome. A report of seven cases. Cancer 1988;62:391-406.
28. Kepes JJ, Moral LA, Wilkinson SB, Abdullah A, Llena JE. Rhabdoid transformation of tumor cells in meningiomas: A histologic indication of increased proliferative activity: Report of four cases. Am J Surg Pathol 1998;22:231-8.
29. Kim E, Weon YC, Kim S, Kim HJ, Byun H, Lee JI, et al. Rhabdoid meningioma: Clinical features and MR imaging findings in 15 patients. Am J Neuroradiol 2007;28:1462-5.
30. Kleihues P, Louis DN, Scheithauer BW, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2000;34:143-50.
31. Ladouceur A, Clarke AE, Ramsey-Goldman R, Bernatsky S. Malignancies in systemic lupus erythematosus: An update. Curr Opin Rheumatol 2019;31:678-81.
32. Matteson EL, Hickey A, Maguire L, Tilson H, Urowitz M. Occurrence of neoplasm in patients with rheumatoid arthritis enrolled in a DMARD registry. Rheumatoid arthritis azathioprine registry steering committee. J Rheumatol 1991;18:809-14.
33. Menon S, Sandesh O, Anand D, Menon G. Spheno-orbital meningiomas: Optimizing visual outcome. J Neurosci Rural Pract 2020;11:385-94.
34. Mourits MP, van der Sprenkel JW. Orbital meningioma, the utrecht experience. Orbit 2001;20:25-33.
35. Nagahama A, Goto T, Nagm A, Tanoue Y, Watanabe Y, Arima H., et al. Spheno-orbital meningioma: Surgical outcomes and management of recurrence. World Neurosurg 2019;126:e679-87.
36. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015;17 Suppl 4:v1-62.
37. Perry A, Scheithauer BW, Stafford SL, Abell-Aleff PC, Meyer FB. Rhabdoid meningioma: An aggressive variant. Am J Surg Pathol 1998;22:1482-90.
38. Plotz PH, Klippel JH, Decker JL, Grauman D, Wolff B, Brown B, et al. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 1979;91:221-3.

39. Pompili A, Derome PJ, Visot A, Guiot G. Hyperostosing meningiomas of the sphenoid ridge-clinical features, surgical therapy, and long-term observations: Review of 49 cases. Surg Neurol 1982;17:411-6.

40. Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol 2017;13:799-814.

41. Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995;38:1120-7.

42. Richardson TT, Cohen PR. Subacute cutaneous lupus erythematosus: Report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin. Cutis 2000;66:183-8.

43. Ringel F, Cedzich C, Schramm J. Microsurgical technique and results of a series of 63 spheno-orbital meningiomas. Neurosurgery 2007;60 Suppl 4:214-21; discussion 221-2.

44. Roser F, Nakamura M, Bellinzona M, Rosahl S, Ostertag H, Samii M. The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 2004;57:1033-7.

45. Ruiz-Irastorza G, Ugarte-A, Egurbide M, Garmendia M, Pijoan J, Martinez-Berriotxoa A, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007;66:815-7.

46. Sade B, Chahalvi A, Krishnaney A, Nagel S, Choi E, Lee JH. World Health Organization Grades II and III meningiomas are rare in the cranial base and spine. Neurosurgery 2007;61:1194-8; discussion 1198.

47. Saeed P, van Furth WR, Tanck M, Kooremans F, Freling N, Streekstra GI, et al. Natural history of sphenoid-orbital meningiomas. Acta Neurochir (Wien) 2011;153:395-402.

48. Sandalcioglu IE, Gasser T, Mohr C, Stolke D, Wiedemayer H. Sphenoid-orbital meningiomas: Interdisciplinary surgical approach, resectability and long-term results. J Craniomaxillofac Surg 2005;33:260-6.

49. Sankaran S, Sankaralingam R. Meningioma and Lupus-A Deadly Duo!-A Report of 2 Cases; 2015:3:1-4.

50. Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Lönn S, Söderberg KC, et al. Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer 2003;106:423-8.

51. Sekhar LN, Möller AR. Operative management of tumors involving the cavernous sinus. J Neurosurg 1986;64:879-89.

52. Shrivastava RK, Sen C, Costantino PD, Rocca RD. Spheno-orbital meningiomas: Surgical limitations and lessons learned in their long-term management. J Neurosurg 2005;103:491-7.

53. Silman AJ, Petrie J, Hazleman B, Evans S. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study. Ann Rheum Dis 1988;47:988-92.

54. Song L, Wang Y, Zhang J, Song N, Xu X, Lu Y. The risks of cancer development in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis. Arthritis Res Ther 2018;20:270.

55. Tallbacka K, Pettersson T, Pukkala E. Increased incidence of cancer in systemic lupus erythematosus: A Finnish cohort study with more than 25 years of follow-up. Scand J Rheumatol 2018;47:461-4.

56. Terrier LM, Bernard F, Fournier HD, Morandi X, Velut S, Hénaux PL, et al. Spheno-orbital meningiomas surgery: Multicenter management study for complex extensive tumors. World Neurosurg 2018;112:e145-56.

57. Wang XQ, Mei GH, Zhao L, Li ST, Gong Y, Zhong J, et al. Clinical features and treatment of intracranial chordoid meningioma: A report of 30 cases. Histopathology 2013;62:1002-17.

58. Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: Clues from genetic and cytokine studies. Clin Rev Allergy Immunol 2011;40:42-9.

59. Yoo BW, Ahn SS, Pyo JY, Byun SJ, Song JJ, Park YB, et al. Brain meningioma in a patient with systemic lupus erythematosus. Yeungnam Univ J Med 2016;33:159-61.

60. Zhou Y, Xie Q, Gong Y, Mao Y, Zhong P, Che X, et al. Clinicopathological analysis of rhabdoid meningiomas: Report of 12 cases and a systematic review of the literature. World Neurosurg 2013;79:724-32.